ストックスクリーナーアプリを入手
0.301
0.66%
-0.002
前日終値:
$0.303
開ける：
$0.31
24時間の取引高:
3.15M
Relative Volume:
0.50
時価総額：
$75.10M
収益：
$21.73M
当期純損益:
$-91.17M
株価収益率:
-0.2951
EPS:
-1.02
ネットキャッシュフロー:
$-286.43M
1週間 パフォーマンス:
-16.99%
1か月 パフォーマンス:
-39.41%
6か月 パフォーマンス:
-69.80%
1年 パフォーマンス:
-91.78%
1日の値動き範囲:
$0.29
$0.3139
1週間の範囲:
$0.29
$0.3699
52週間の値動き範囲:
$0.29
$5.53
Bluebird Bio Inc Stock (BLUE) Company Profile
名前
Bluebird Bio Inc
セクター
電話
339-499-9300
住所
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BLUE | 0.3009 | 75.10M | 21.73M | -91.17M | -286.43M | -1.02 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.68 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-28 | 開始されました | JP Morgan | Overweight |
| 2023-03-07 | 開始されました | Robert W. Baird | Outperform |
| 2022-08-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-08-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-03-07 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-11-08 | 繰り返されました | Canaccord Genuity | Hold |
| 2021-11-08 | ダウングレード | Goldman | Neutral → Sell |
| 2021-11-08 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 繰り返されました | Wedbush | Neutral |
| 2021-11-08 | 繰り返されました | Wells Fargo | Equal Weight |
| 2021-08-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | ダウングレード | Goldman | Buy → Neutral |
| 2021-08-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 再開されました | William Blair | Mkt Perform |
| 2021-08-09 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | ダウングレード | Berenberg | Buy → Hold |
| 2021-03-10 | アップグレード | Mizuho | Neutral → Buy |
| 2021-02-17 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-02-16 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-16 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-05 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-11-05 | ダウングレード | Stifel | Buy → Hold |
| 2020-11-02 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 開始されました | Mizuho | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-27 | アップグレード | Stifel | Hold → Buy |
| 2020-02-19 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 再開されました | BofA/Merrill | Buy |
| 2020-02-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-11-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-04 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-10-01 | 開始されました | Stifel | Hold |
| 2019-08-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | アップグレード | Maxim Group | Hold → Buy |
すべてを表示
Bluebird Bio Inc (BLUE) 最新ニュース
Bluebird Bio's SWOT analysis: gene therapy firm faces cash crunch amid launch - Investing.com
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR
bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat
B of A Securities Downgrades bluebird bio (BLUE) - MSN
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL
Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN
bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA
bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha
Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com Canada
bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Barclays - MarketBeat
Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com
bluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat
JPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to Underweight - MarketBeat
bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St
Bluebird: Q3 Earnings Snapshot - Darien Times
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Naviga - GuruFocus.com
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
Bluebird bio Reports Q3 2024 Earnings and Future Outlook - TipRanks
bluebird bio Inc (BLUE) Quarterly 10-Q Report - Quartz
Earnings call: Bluebird bio sees patient growth, aims for 2025 breakeven - Investing.com
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - citybiz
Bluebird bio says it needs cash to operate beyond March 2025 - The Business Journals
Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
BLUE (bluebird bio) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
Q3 2024 bluebird bio Inc Earnings Call Transcript - GuruFocus.com
bluebird bio Q3 Revenue Dips to $10.6M, Eyes Break-Even by 2025 Despite Losses | BLUE Stock News - StockTitan
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, - openPR
bluebird bio Q3 2024 Earnings Preview - MSN
Goldman Sachs Group Inc's Strategic Acquisition of Shares in blu - GuruFocus.com
Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR
Eagle Pharmaceuticals Taps Former Bluebird Bio CFO Krawtschuk to Lead Finance | EGRX Stock News - StockTitan
bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter 2024 Results Call - BioSpace
bluebird bio expands incentive plan amid leadership changes - Investing.com India
Bluebird Bio’s Key Decisions and Shareholder Engagement in 2024 - TipRanks
bluebird bio expands incentive plan amid leadership changes By Investing.com - Investing.com UK
bluebird bio Delays Stock Split Vote, Faces Nasdaq Delisting Risk Amid Capital Needs | BLUE Stock News - StockTitan
What's Going On With Bluebird Bio Stock? - MSN
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - BioSpace
Bluebird bio stock plunges to 52-week low of $0.45 amid downturn - Investing.com Australia
BLUE (bluebird bio) Cyclically Adjusted FCF per Share : $-7.77 (As of Jun. 2024) - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition of Shares in bluebird bio Inc - GuruFocus.com
StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat
7 children given bluebird's Skysona developed blood cancer: study - MSN
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies - Insider Monkey
Bluebird Bio Inc (BLUE) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):